Table 1. Patient characteristics of the study cohort.
| Patient characteristics | All patients (n = 10) |
|---|---|
| Age (years) | 64 (47–73) |
| Sex (male) | 10 (100%) |
| Weight (kg) | 85 (78–97) |
| Height (cm) | 178 (173–185) |
| BMI (kg m-2) | 26 (25–29) |
| Obesity (BMI >30 kg m-2) | 2 (20%) |
| Hypertension | 4 (40%) |
| Diabetes mellitus | 4 (40%) |
| Heart disease | 0 (0%) |
| Previous or current PE | 0 (0%) |
| Asthma | 2 (20%) |
| COPD | 0 (0%) |
| Chronic renal failure | 1 (10%) |
| Malignancy | 1 (10%) |
| Active smoker | 0 (0%) |
| Previous smoker | 4 (40%) |
| Days with symptoms | 13 (9–16) |
| Days hospitalized | 5 (4–9) |
| Days ICU | 3 (2–6) |
| HFNO | 5 (50%) |
| Flow (L min-1) median (range) | 50 (50–60) |
| NIV | 5 (50%) |
| PEEP (cmH2O) median (range) | 8 (5–12) |
| PS (cmH2O) median (range) | 5 (3–5) |
| FiO2 | 0.5 (0.4–0.65) |
| SpO2 (%) | 94 (93–95) |
| PaO2 (kPa) | 9.6 (8.9–10.0) |
| PaO2 (mmHg) | 72 (67–75) |
| PaO2/FiO2 ratio (kPa) | 18.9 (14.7–21.5) |
| PaO2/FiO2 ratio (mmHg) | 142 (110–161) |
| Heart rate (min-1) | 66 (55–75) |
| Mean arterial pressure (mmHg) | 80 (72–86) |
| Remdesevir | 4 (40%) |
| LMWH prophylaxis | 10 (100%) |
| Dexamethasone | 10 (100%) |
| Antibiotics | 5 (50%) |
| Vasopressor | 0 (0%) |
| Dexmedetomidine | 6 (60%) |
| C-reactive protein (mg L-1) | 54 (21–66) |
| Procalcitonin (μg L-1) | 0.19 (0.11–0.60) |
| Ferritin (n = 9) (μg L-1) | 985 (848–1348) |
| Hemoglobin (g L-1) | 141 (129–148) |
| D-dimer (mg L-1) | 1.2 (0.5–2.1) |
| Creatinine (μmol L-1) | 71 (26–110) |
| Troponin-I (ng L-1) | 9 (6–13) |
| NT-pro-BNP (n = 9) (ng L-1) | 243 (157–494) |
| SOFA score | 3 (3–5) |
| Temperature (°C) | 37.1 (36.7–37.8) |
Data are presented as median (IQR) or numbers (percentages). BMI, body mass index. HFNO, high-flow nasal oxygen. NIV, non-invasive ventilation. PEEP, positive end-expiratory pressure. PS, pressure support. COPD, chronic obstructive pulmonary disease. LMWH, low molecular weight heparin. NT-pro-BNP, N-terminal prohormone of brain natriuretic peptide. PE, Pulmonary embolism. SOFA, sequential organ failure assessment.